| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Sarcoma | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Histiocytoma | |||||
| Histiocytoma, Benign Fibrous | |||||
| Histiocytoma, Malignant Fibrous | |||||
| 3 | More general conditions related to this trial | ||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms, Connective and Soft Tissue | |||||
| Neoplasms, Connective Tissue | |||||
| Neoplasms, Fibrous Tissue | |||||
| 4 | Interventions listed in this trial | ||||
| imatinib mesylate | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Imatinib | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Protein Kinase Inhibitors | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| NCI - Center for Cancer Research-Medical Oncology | |||||
| National Cancer Institute (NCI) | |||||
|
